1 |
Dixon RA, Steele CL. Flavonoids and isoflavonoids - a gold mine for metabolic engineering. Trends Plant Sci 1999; 4: 394-400.
DOI
ScienceOn
|
2 |
Stahelin HF, von Wartburg A. The chemical and biological route from podophyllotoxin glucoside to etoposide: Ninth Cain memorial award lecture. Cancer Res 1991; 51: 5-15.
|
3 |
Clark PI, Slevin ML. The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 1987; 12: 223-252.
DOI
ScienceOn
|
4 |
Wozniak AJ, Ross WE. DNA damage as a basis for 4'- demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-Dglucopyranoside) (etoposide) cytotoxicity. Cancer Res 1983; 43: 120-124.
|
5 |
van Maanen JM, de Vries J, Pappie D. Cytochrome P- 450-mediated O-demethylation: a route in the metabolic activation of etoposide (VP-16-213). Cancer Res 1987; 47: 4658-4662.
|
6 |
Relling MV, Nemec J, Schuetz EG, et al., Odemethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 1994; 45: 352-358.
|
7 |
Kawashiro T, Yamashita K, Zhao XJ, et al., A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther 1998; 286: 1294- 1300.
|
8 |
Leu BL, Huang JD. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 1995; 35: 432-436.
DOI
ScienceOn
|
9 |
Carcel-Trullols J, Torres-Molina F, Araico A, et al., Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide. Cancer Chemother Pharmacol 2004; 54: 153- 160.
|
10 |
Keller RP, Altermatt HJ, Donatsch P, et al., Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int J Cancer 1992; 51: 433- 438.
DOI
|
11 |
Yin Y, Gong FY, Wu XX, et al., Anti-inflammatory and immunosuppressive effect of flavones isolated from Artemisia vestita. J Ethnopharmacol 2008; 120: 1-6.
DOI
ScienceOn
|
12 |
Nafisi S, Hashemi M, Rajabi M. DNA Adducts with Antioxidant Flavonoids: Morin, Apigenin, and Naringin. DNA and Cell Biology 2008; 27: 1-10.
DOI
ScienceOn
|
13 |
Galati G, Moridani MY, Chan TS, et al., Peroxidative metabolism of apigenin and naringenin versus luteolin and quercetin: glutathione oxidation and conjugation. Free Radical Biology & Medicine. 2001; 30: 370-382.
DOI
ScienceOn
|
14 |
Chuang CM, Monie A, Wu A, et al., Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects. J Biomed Sci 2009; 16: 49-60.
DOI
|
15 |
Ho PC, Saville DJ, Wanwimolruk S. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 2001; 4: 217- 227.
|
16 |
Jeong GS, Lee SH, Jeong SN, et al., Anti-inflammatory effects of apigenin on nicotine- and lipopolysaccharidestimulated human periodontal ligament cells via heme oxygenase-1. Int Immunopharmacol 2009; 9: 1374-1380.
DOI
ScienceOn
|
17 |
Gates MA, Vitonis AF, Tworoger SS, et al., Flavonoid intake and ovarian cancer risk in a population-based case-control study. Int J Cancer 2009; 124: 1918-1925.
DOI
ScienceOn
|
18 |
Fukuda K, Ohta T, Oshima Y, et al., Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 1997; 7: 391-396.
DOI
ScienceOn
|
19 |
Critchfield JW, Welsh CJ, Phang JM, et al., Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem Pharmacol 1994; 48: 1437-1445.
DOI
ScienceOn
|
20 |
Nguyen H, Zhang S, Morris ME. Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci 2003; 92; 250-257.
DOI
ScienceOn
|
21 |
Kimura Y, Ito H, Ohnishi R, et al., Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem Toxicol 2010; 48: 429-435.
DOI
ScienceOn
|
22 |
Li X, Yun JK, Choi JS. Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos 2007; 28: 151-156.
DOI
ScienceOn
|
23 |
Benet LZ, Cummins CL, Wu CY. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 2003; 4: 393- 398.
DOI
ScienceOn
|
24 |
Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002; 300: 1036-1045.
DOI
ScienceOn
|
25 |
Kelly PA, Wang H, Napoli KL, et al., Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur J Drug Metab Pharmacokinet 1999; 24: 321-328.
DOI
ScienceOn
|
26 |
Cao X, Gibbs ST, Fang L, et al., Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 2006; 23: 1675-1686.
DOI
ScienceOn
|
27 |
Li X, Choi JS. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats. Int J Pharm 2007; 337: 188-193.
DOI
ScienceOn
|
28 |
Li X, Choi JS. Effects of quercetin on the pharmacokinetics of etoposide after oral and intravenouse administration of etoposide in rats. Anticancer Research 2009; 29: 1411-1416.
|
29 |
Piao Y, Shin SC, Choi JS. Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rats. Biopharm Drug Dispos 2008; 29: 245-249.
DOI
ScienceOn
|